An interventional study of ProMIO2.0 program in Sarcopenia, Diabetes and Overweight, sponsored by Amsterdam University of Applied Sciences. Completed at 1 site in Netherlands. Open to participants aged 55 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-09.
Sponsored by Amsterdam University of Applied Sciences · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Sarcopenia with a site in Netherlands — 1 open to participants now, 2 under way, none of them phase 3. Sarcopenia · Netherlands.
Among the 32 studies in Sarcopenia with a site in Netherlands, this one is the 7th largest by enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2022, is one of 23 with no phase, and was the 29th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →1 of the 32 studies in Sarcopenia with a site in Netherlands is open now. Recruiting first, the newest first:
Radboud University Medical Center · Sites in Netherlands
Ages 65+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 55 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 4 2
First in 2007; this study’s year is marked. 5 started in 2022.
This study's enrollment of 76 is above the median of 60 across 860 interventional studies indexed under Sarcopenia.
Median enrollment 45 across the 29 interventional studies, 140 across the 3 observational. Of the 28 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 32 have an industry lead sponsor. The 10 most frequent:
Amsterdam University of Applied Sciences is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Amsterdam University of Applied Sciences has 1 study filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 32 studies in Sarcopenia with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Older adults from ethnic minorities show on average a worse disease risk profile compared to the majority populations. An important risk factor to develop chronic diseases is the loss of muscle mass and functioning, also known as sarcopenia. Several randomized controlled trials (RCTs) showed that the combination of adequate protein intake and physical exercise is most effective to prevent the loss of muscle mass, strength and functioning in older adults. However, until shortly, no intervention that included protein and exercise was available that accounted for the special socio-cultural needs of ethnic minority populations. Therefore the Amsterdam University of Applied Sciences (AUAS) and ProMIO project group developed a cultural sensitive lifestyle intervention with protein and exercise carried out by dieticians and physical therapists to provide a tailored treatment for older adults from ethnic minorities. This project aims to evaluate the effectiveness of this new intervention on protein intake, physical activity behavior, muscle mass, muscle strength, function and quality of life. The cost-effectiveness of this new intervention will also be evaluated.
Primary Objective: To investigate the effectiveness of the ProMIO lifestyle intervention (targeting protein intake and exercise behavior) on physical functioning, in older adults from ethnic minorities (Surinamese).
The intervention will be a lifestyle intervention targeted at changing health behaviors in older adults from ethnic minorities in the Netherlands. Methods will be used that target specific behavioral determinants in order to optimize both exercise and dietary behavior. We aim to reach the following behavioral outcomes:
Reaching the WHO physical activity guidelines for older adults:
Based on previous research it is expected that by optimizing these health behaviors, muscle mass, muscle strength, and physical functioning will improve.
Secondary Objective(s):
The (cost-)effectiveness of the ProMIO intervention will be investigated using a single blind randomized controlled trial (RCT) with two parallel arms.
First, potential participants will be recruited and screened for eligibility. Secondly, participants will be randomly assigned to one of the two groups; the intervention group or the control group.
The full study will comprise a 6-month intervention, divided in two phases, and consisting of a multicomponent exercise training (MCE) program provided by physical therapists and a protein intervention provided by dieticians. Each participant will be supervised and monitored by a physical therapist and a dietician, who are providing regular consulting sessions.
Exercise activities, like group exercise training, will be provided by certified trainers and health education will be provided by AUAS graduate students with a background in nutrition and/or physical exercise. Certified trainers and graduate students are supervised and guided by the physical therapist and dietician. The intensity of the professional support during the intervention will be highest in the first phase and taper off during the second phase. Participants are expected to adopt most of the desired behavioral activities in daily living without professional help. Data will be collected at baseline (T1) and after 3 (T2), and 6 (T3) months.
Outcome measures are a combination between quantitative and qualitative outcome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving regular care in the 6 months period. They receive a brief education session at start about exercise and protein.
Participants receiving regular care and our newly developed lifestyle intervention for 6 months period. The intervention is culture specific and contains of: * Dietetic care focused on protein intake (protein counselling) * Multicomponent exercise (physical therapy); a combination between group sessions and home-based exercise The first 3 months are intensive phase, second 3 months guidance gradually decreases.
Behavioral: ProMIO2.0 program
ProMIO2.0 is a lifestyle intervention carried out by physiotherapy and dietetics. They guide and encourage the participants to achieve the following behavioral goals: * moderate/intensive exercise (e.g. walking) for 150-300 minutes per week * Muscle-strengthening exercises 2x a week * Supplemented with balance and flexibility exercises * 1.2 grams of protein per kilogram of body weight per day (\~25-30 grams of protein per meal, 4x/day) The combination of consultations, information sessions and on-site training at the physiotherapist should ensure that participants acquire the necessary knowledge, awareness and skills to adopt the health behavior in daily life. Materials such as posters, pedometers and videos are used for support. The intervention is divided into 2 phases, which indicate the degree of professional guidance: 1. intensive guidance (month 0 - 3) 2. average guidance (months 4 - 6)
Physical functioning
change in meters from baseline to 3 months by 6 Minute Walk Test
Time frame: baseline, 3 months
Physical functioning
change in meters from baseline to 6 months by 6 Minute Walk Test
Time frame: baseline, 6 months
30-sec Chair Stand Test
(frequency) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Balance (Single Leg Stand Test)
(seconds) - change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Strenght (1RM with Microfet)
(kg) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Strenght with Hand Grip Strenght
(kg) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Body composition Lenght
(meters) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Body composition Weight
(kg) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Body composition BMI
(kg/m2) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Body composition 2D muscle echo
(cm2) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Behavioral outcome - Dietary intake (48h recall)
macronutrient and micronutrient change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Behavioral outcome - Physical Activity
(PAMscore) - change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Quality of Life (QoL)
(score) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Sarcopenia screening (SarQoL)
(score) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Frailty
(score) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Activities of Daily Living (ADL) Katz
(score) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Pain (NRS)
(NRS) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Sleep (NRS)
(NRS) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Risk of Falls (NRS)
(NRS) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Efficacy Scale International (sFES-I)
(score) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
symptoms of depression (CES-D)
(score) change from baseline to 3 or 6 months
Time frame: baseline, 3 months, 6 months
Cost effectiveness - Productivity Cost Questionnaire (PCQ)
(score) change from baseline to 6 months
Time frame: baseline, 6 months
Cost effectiveness - Cost of Quality (MCQ)
(score) change from baseline to 6 months
Time frame: baseline, 6 months
Process evaluation
Process evaluation questionnaire and focus group sessions
Time frame: 6 months
Social democrafic characteristics
e.g. age (years), gender (f/m), highest education level
Time frame: screening, baseline
Medical history
all medical events and diseases reported
Time frame: screening
Medication use
all medication reported at start and during the trial
Time frame: screening and during study
Adverse events
all adverse events reported during the intervention study
Time frame: During study
Adherence to the intervention
Specified for exercise routine and protein intake; a % of attendance and minimal 1.2 g/kgBW/day protein intake
Time frame: During study
Plan to share: Yes — Restricted on Figshare following our OpenScience regulations
Supporting information: Study protocol, Informed consent form, Clinical study report
Time frame: After study completion
Access criteria: Restricted untill publication.
Ran from May 2022 to primary completion in Jun 2023, 12 months.
Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 12 months is below that.
Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amsterdam University of Applied Sciences